Cargando…
Prognostic Role of Adjuvant Chemotherapy in Node-Negative (N0), Triple-Negative (TN), Medullary Breast Cancer (MBC) in the Korean Population
BACKGROUND: Despite the favorable prognosis for medullary breast cancer (MBC), the guidelines for the use of adjuvant chemotherapy for MBC have not been clearly established. This study investigated the prognostic role of adjuvant chemotherapy in Korean patients with node-negative (N0), triple-negati...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4642937/ https://www.ncbi.nlm.nih.gov/pubmed/26562837 http://dx.doi.org/10.1371/journal.pone.0140208 |
_version_ | 1782400436268957696 |
---|---|
author | Lim, SeungTaek Park, Se Ho Park, Heong Kyu Hur, Min Hee Oh, Se Jeong Suh, Young Jin |
author_facet | Lim, SeungTaek Park, Se Ho Park, Heong Kyu Hur, Min Hee Oh, Se Jeong Suh, Young Jin |
author_sort | Lim, SeungTaek |
collection | PubMed |
description | BACKGROUND: Despite the favorable prognosis for medullary breast cancer (MBC), the guidelines for the use of adjuvant chemotherapy for MBC have not been clearly established. This study investigated the prognostic role of adjuvant chemotherapy in Korean patients with node-negative (N0), triple-negative (TN) MBC patients. METHODS: We included data from 252 patients with N0 TN MBC, obtained from the Korean Breast Cancer Registry database. Patients were categorized as those who did not undergo adjuvant chemotherapy (group I) or those who did (group II). Clinicopathological characteristics, breast cancer-specific survival (BCSS), and overall survival (OS) were compared between the groups. In addition, a subgroup analysis for survival based on tumor size was conducted. RESULTS: A total of 252 N0 TN MBC patients with tumor sizes >1 cm who were diagnosed between April 1997 and March 2011 were enrolled. The median age was 44.95 years (range, 25–72 years), and the median follow-up period was 93.94 months (range, 23–195 months). Overall, the BCSS and OS in group II (97.3% and 97.3%, respectively) were significantly better compared with those in group I (89.2% and 86.2%, respectively). In the subgroup analysis, in patients with tumors >2 cm in size, those in group II had significant better BCSS and OS (97.5% and 97.5%, respectively) compared with those in group I (78.3% and 73.9%, respectively). In contrast in those with tumors 1–2 cm in size, there were no significant differences in BCSS and OS between the groups (both 97.1% for group I, and 95.2% and 92.9%, respectively for group II). Multivariate analysis revealed that adjuvant chemotherapy significantly improved BCSS (P = 0.009) and OS (P = 0.007), but only for patients with larger tumors (>2 cm). CONCLUSIONS: In patients with N0 TN MBC, adjuvant chemotherapy had a significant clinical survival benefit, but only in those with tumors >2 cm. |
format | Online Article Text |
id | pubmed-4642937 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-46429372015-11-18 Prognostic Role of Adjuvant Chemotherapy in Node-Negative (N0), Triple-Negative (TN), Medullary Breast Cancer (MBC) in the Korean Population Lim, SeungTaek Park, Se Ho Park, Heong Kyu Hur, Min Hee Oh, Se Jeong Suh, Young Jin PLoS One Research Article BACKGROUND: Despite the favorable prognosis for medullary breast cancer (MBC), the guidelines for the use of adjuvant chemotherapy for MBC have not been clearly established. This study investigated the prognostic role of adjuvant chemotherapy in Korean patients with node-negative (N0), triple-negative (TN) MBC patients. METHODS: We included data from 252 patients with N0 TN MBC, obtained from the Korean Breast Cancer Registry database. Patients were categorized as those who did not undergo adjuvant chemotherapy (group I) or those who did (group II). Clinicopathological characteristics, breast cancer-specific survival (BCSS), and overall survival (OS) were compared between the groups. In addition, a subgroup analysis for survival based on tumor size was conducted. RESULTS: A total of 252 N0 TN MBC patients with tumor sizes >1 cm who were diagnosed between April 1997 and March 2011 were enrolled. The median age was 44.95 years (range, 25–72 years), and the median follow-up period was 93.94 months (range, 23–195 months). Overall, the BCSS and OS in group II (97.3% and 97.3%, respectively) were significantly better compared with those in group I (89.2% and 86.2%, respectively). In the subgroup analysis, in patients with tumors >2 cm in size, those in group II had significant better BCSS and OS (97.5% and 97.5%, respectively) compared with those in group I (78.3% and 73.9%, respectively). In contrast in those with tumors 1–2 cm in size, there were no significant differences in BCSS and OS between the groups (both 97.1% for group I, and 95.2% and 92.9%, respectively for group II). Multivariate analysis revealed that adjuvant chemotherapy significantly improved BCSS (P = 0.009) and OS (P = 0.007), but only for patients with larger tumors (>2 cm). CONCLUSIONS: In patients with N0 TN MBC, adjuvant chemotherapy had a significant clinical survival benefit, but only in those with tumors >2 cm. Public Library of Science 2015-11-12 /pmc/articles/PMC4642937/ /pubmed/26562837 http://dx.doi.org/10.1371/journal.pone.0140208 Text en © 2015 Lim et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Lim, SeungTaek Park, Se Ho Park, Heong Kyu Hur, Min Hee Oh, Se Jeong Suh, Young Jin Prognostic Role of Adjuvant Chemotherapy in Node-Negative (N0), Triple-Negative (TN), Medullary Breast Cancer (MBC) in the Korean Population |
title | Prognostic Role of Adjuvant Chemotherapy in Node-Negative (N0), Triple-Negative (TN), Medullary Breast Cancer (MBC) in the Korean Population |
title_full | Prognostic Role of Adjuvant Chemotherapy in Node-Negative (N0), Triple-Negative (TN), Medullary Breast Cancer (MBC) in the Korean Population |
title_fullStr | Prognostic Role of Adjuvant Chemotherapy in Node-Negative (N0), Triple-Negative (TN), Medullary Breast Cancer (MBC) in the Korean Population |
title_full_unstemmed | Prognostic Role of Adjuvant Chemotherapy in Node-Negative (N0), Triple-Negative (TN), Medullary Breast Cancer (MBC) in the Korean Population |
title_short | Prognostic Role of Adjuvant Chemotherapy in Node-Negative (N0), Triple-Negative (TN), Medullary Breast Cancer (MBC) in the Korean Population |
title_sort | prognostic role of adjuvant chemotherapy in node-negative (n0), triple-negative (tn), medullary breast cancer (mbc) in the korean population |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4642937/ https://www.ncbi.nlm.nih.gov/pubmed/26562837 http://dx.doi.org/10.1371/journal.pone.0140208 |
work_keys_str_mv | AT limseungtaek prognosticroleofadjuvantchemotherapyinnodenegativen0triplenegativetnmedullarybreastcancermbcinthekoreanpopulation AT parkseho prognosticroleofadjuvantchemotherapyinnodenegativen0triplenegativetnmedullarybreastcancermbcinthekoreanpopulation AT parkheongkyu prognosticroleofadjuvantchemotherapyinnodenegativen0triplenegativetnmedullarybreastcancermbcinthekoreanpopulation AT hurminhee prognosticroleofadjuvantchemotherapyinnodenegativen0triplenegativetnmedullarybreastcancermbcinthekoreanpopulation AT ohsejeong prognosticroleofadjuvantchemotherapyinnodenegativen0triplenegativetnmedullarybreastcancermbcinthekoreanpopulation AT suhyoungjin prognosticroleofadjuvantchemotherapyinnodenegativen0triplenegativetnmedullarybreastcancermbcinthekoreanpopulation |